Enliven Therapeutics ELVN Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$98.78M-4.2% | -$103.69M-16.5% | -$97.21M-14.1% | -$100.22M-21.0% | -$94.83M-19.1% | ||
| $203K-34.9% | $263K-17.0% | $297K-5.7% | $315K+0.6% | $312K+1.0% | ||
| $34.62M+54.1% | $34.02M+68.6% | $27.05M+51.2% | $25.04M+55.4% | $22.46M+48.1% | ||
| -$65.47M+11.5% | -$70.3M+3.9% | -$71.67M-4.7% | -$70.58M+2.2% | -$73.96M-15.9% | ||
| —— | —— | —— | $181K+248% | $44K-68.1% | ||
| -$145.12M— | -$186.22M— | —— | —— | —— | ||
| $229.05M+431% | $219.24M+64.6% | $258.58M+177% | $259.7M— | $43.13M— | ||
| —— | —— | —— | —— | -$47.51M— | ||
| -$65.6M+11.3% | -$70.46M+3.8% | -$71.82M-4.8% | -$70.76M+2.0% | -$74M-15.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Enliven Therapeutics generate?
- Enliven Therapeutics (ELVN) generated -$65.5M in operating cash flow over the trailing twelve months.
- What is Enliven Therapeutics's free cash flow?
- After $159.0K of capital expenditures, Enliven Therapeutics's free cash flow was -$65.6M over the trailing twelve months, up 11.3% year over year.
- Where does Enliven Therapeutics's cash flow data come from?
- Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.